Seminars in Oncology
Volume 31, Issue 4 , Pages 476-486 , August 2004

Molecular biology of upper gastrointestinal malignancies

  • Jules Lin

      Affiliations

    • Corresponding Author InformationAddress reprint requests to David G. Beer, Department of Surgery, Section of General Thoracic Surgery, MSRB II B560, Box 0686, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    • Section of General Thoracic Surgery, Department of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA
    • ,
  • David G. Beerm

      Affiliations

    • Section of General Thoracic Surgery, Department of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA

References 

  1. Devesa SS, Blot WJ, Fraumeni JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83:2049–2053
  2. Jemal A, Thomas A, Murray T, et al.  Cancer statistics, 2002. CA Cancer J Clin. 2002;52:23–47
  3. Cameron AJ, Carpenter HA. Barrett’s esophagus, high-grade dysplasia, and early adenocarcinoma (A pathological study). Am J Gastroenterol. 1997;92:586–591
  4. Mendes de Almeida JC, Chaves P, Pereira AD, et al.  Is Barrett’s esophagus the precursor of most adenocarcinomas of the esophagus and cardia? A biochemical study. Ann Surg. 1997;226:725–733
  5. Zhuang Z, Vortmeyer AO, Mark EJ, et al.  Barrett’s esophagus (Metaplastic cells with loss of heterozygosity at the APC gene locus are clonal precursors to invasive adenocarcinoma). Cancer Res. 1996;56:1961–1964
  6. Hameeteman W, Tytgat GN, Houthoff HJ, et al.  Barrett’s esophagus (development of dysplasia and adenocarcinoma). Gastroenterology. 1989;96:1249–1256
  7. Reid BJ, Blount PL, Rubin CE, et al.  Flow-cytometric and histological progression to malignancy in Barrett’s esophagus (Prospective endoscopic surveillance of a cohort). Gastroenterology. 1992;102:1212–1219
  8. Weiss MM, Kuipers EJ, Hermsen MA, et al.  Barrett’s adenocarcinomas resemble adenocarcinomas of the gastric cardia in terms of chromosomal copy number changes, but relate to squamous cell carcinomas of the distal oesophagus with respect to the presence of high-level amplifications. J Pathol. 2003;199:157–165
  9. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70
  10. Regalado SP, Nambu Y, Iannettoni MD, et al.  Abundant expression of the intestinal protein villin in Barrett’s metaplasia and esophageal adenocarcinomas. Mol Carcinog. 1998;22:182–189
  11. Iannettoni MD, Lee SS, Bonnell MR, et al.  Detection of Barrett’s adenocarcinoma of the gastric cardia with sucrase isomaltase and p53. Ann Thorac Surg. 1996;62:1460–1465
  12. Beilstein M, Silberg D. Cellular and molecular mechanisms responsible for progression of Barrett’s metaplasia to esophageal carcinoma. Gastroenterol Clin North Am. 2002;31:461–479
  13. Shinohara M, Aoki T, Sato S, et al.  Cell cycle-regulated factors in esophageal cancer. Dis Esophagus. 2002;15:149–154
  14. Casson AG. Role of molecular biology in the follow-up of patients who have Barrett’s esophagus. Chest Surg Clin North Am. 2002;12:93–111
  15. Jenkins GJ, Doak SH, Parry JM, et al.  Genetic pathways involved in the progression of Barrett’s metaplasia to adenocarcinoma. Br J Surg. 2002;89:824–837
  16. Coppola D, Schreiber RH, Mora L, et al.  Significance of Fas and retinoblastoma protein expression during the progression of Barrett’s metaplasia to adenocarcinoma. Ann Surg Oncol. 1999;6:298–304
  17. Galipeau PC, Prevo LJ, Sanchez CA, et al.  Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett’s) tissue. J Natl Cancer Inst. 1999;91:2087–2095
  18. Xing EP, Nie Y, Song Y, et al.  Mechanisms of inactivation of p14ARF, p15INK4b, and p16INK4a genes in human esophageal squamous cell carcinoma. Clin Cancer Res. 1999;5:2704–2713
  19. Schrump DS, Chen GA, Consuli U, et al.  Inhibition of esophageal cancer proliferation by adenovirally mediated delivery of p16INK4. Cancer Gene Ther. 1996;3:357–364
  20. Singh SP, Lipman J, Goldman H, et al.  Loss or altered subcellular localization of p27 in Barrett’s associated adenocarcinoma. Cancer Res. 1998;58:1730–1735
  21. Arber N, Lightdale C, Rotterdam H, et al.  Increased expression of the cyclin D1 gene in Barrett’s esophagus. Cancer Epidemiol Biomarkers Prev. 1996;5:457–459
  22. Sarbia M, Bektas N, Muller W, et al.  Expression of cyclin E in dysplasia, carcinoma, and nonmalignant lesions of Barrett esophagus. Cancer. 1999;86:2597–2601
  23. Souza RF, Morales CP, Spechler SJ. Review article (A conceptual approach to understanding the molecular mechanisms of cancer development in Barrett’s oesophagus). Aliment Pharmacol Ther. 2001;15:1087–1100
  24. Lin L, Prescott MS, Zhu Z, et al.  Identification and characterization of a 19q12 amplicon in esophageal adenocarcinomas reveals cyclin E as the best candidate gene for this amplicon. Cancer Res. 2000;60:7021–7027
  25. Miller CT, Moy JR, Lin L, et al.  Gene amplification in esophageal adenocarcinomas and Barrett’s with high-grade dysplasia. Clin Cancer Res. 2003;9:4819–4825
  26. Wijnhoven BP, Tilanus HW, Dinjens WN. Molecular biology of Barrett’s adenocarcinoma. Ann Surg. 2001;233:322–337
  27. Casson AG, Mukhopadhyay T, Cleary KR, et al.  Oncogene activation in esophageal cancer. J Thorac Cardiovasc Surg. 1991;102:707–709
  28. Casson AG, Wilson SM, McCart JA, et al.  ras mutation and expression of the ras-regulated genes osteopontin and cathepsin L in human esophageal cancer. Int J Cancer. 1997;72:739–745
  29. Galiana C, Lozano JC, Bancel B, et al.  High frequency of Ki-ras amplification and p53 gene mutations in adenocarcinomas of the human esophagus. Mol Carcinog. 1995;14:286–293
  30. Miyazaki S, Sasno H, Shiga K, et al.  Analysis of c-myc oncogene in human esophageal carcinoma (Immunohistochemistry, in situ hybridization and northern and Southern blot studies). Anticancer Res. 1992;12:1747–1755
  31. Hughes SJ, Nambu Y, Soldes OS, et al.  Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma. Cancer Res. 1997;57:5571–5578
  32. Casson AG, Tammemagi M, Eskandarian S, et al.  p53 alterations in oesophageal cancer (Association with clinicopathological features, risk factors, and survival). Mol Pathol. 1998;51:71–79
  33. Bongiorno PF, al-Kasspooles M, Lee SW, et al.  E-cadherin expression in primary and metastatic thoracic neoplasms and in Barrett’s oesophagus. Br J Cancer. 1995;71:166–172
  34. Hughes SJ, Glover TW, Zhu XX, et al.  A novel amplicon at 8p22-23 results in overexpression of cathepsin B in esophageal adenocarcinoma. Proc Natl Acad Sci USA. 1998;95:12410–12415
  35. Riegman PH, Vissers KJ, Alers JC, et al.  Genomic alterations in malignant transformation of Barrett’s esophagus. Cancer Res. 2001;61:3164–3170
  36. Reid BJ, Levine DS, Longton G, et al.  Predictors of progression to cancer in Barrett’s esophagus (Baseline histology and flow cytometry identify low- and high-risk patient subsets). Am J Gastroenterol. 2000;95:1669–1676
  37. Wu TT, Watanabe T, Heitmiller R, et al.  Genetic alterations in Barrett esophagus and adenocarcinomas of the esophagus and esophagogastric junction region. Am J Pathol. 1998;153:287–294
  38. Dunn J, Garde J, Dolan K, et al.  Multiple target sites of allelic imbalance on chromosome 17 in Barrett’s oesophageal cancer. Oncogene. 1999;18:987–993
  39. Lam AK. Molecular biology of esophageal squamous cell carcinoma. Crit Rev Oncol Hematol. 2000;33:71–90
  40. Taniere P, Martel-Planche G, Saurin JC, et al.  TP53 mutations, amplification of P63 and expression of cell cycle proteins in squamous cell carcinoma of the oesophagus from a low incidence area in Western Europe. Br J Cancer. 2001;85:721–726
  41. Anayama T, Furihata M, Ishikawa T, et al.  Positive correlation between p27Kip1 expression and progression of human esophageal squamous cell carcinoma. Int J Cancer. 1998;79:439–443
  42. Iihara K, Shiozaki H, Tahara H, et al.  Prognostic significance of transforming growth factor-alpha in human esophageal carcinoma. Implication for the autocrine proliferation. Cancer. 1993;71:2902–2909
  43. Suo Z, Su W, Holm R, et al.  Lack of expression of c-erbB-2 oncoprotein in human esophageal squamous cell carcinomas. Anticancer Res. 1995;15:2797–2798
  44. Ruol A, Stephens JK, Michelassi F, et al.  Expression of ras oncogene p21 protein in esophageal squamous cell carcinoma. J Surg Oncol. 1990;44:142–145
  45. Jankowski J, Coghill G, Hopwood D, et al.  Oncogenes and onco-suppressor gene in adenocarcinoma of the oesophagus. Gut. 1992;33:1033–1038
  46. Flejou JF, Gratio V, Muzeau F, et al.  p53 abnormalities in adenocarcinoma of the gastric cardia and antrum. Mol Pathol. 1999;52:263–268
  47. Hirai T, Kuwahara M, Yoshida K, et al.  Clinical results of transhiatal esophagectomy for carcinoma of the lower thoracic esophagus according to biological markers. Dis Esophagus. 1998;11:221–225
  48. Boynton RF, Blount PL, Yin J, et al.  Loss of heterozygosity involving the APC and MCC genetic loci occurs in the majority of human esophageal cancers. Proc Natl Acad Sci USA. 1992;89:3385–3388
  49. Chanvitan A, Puttawibul P, Casson AG. Flow cytometry in squamous cell esophageal cancer and precancerous lesions. Dis Esophagus. 1997;10:206–210
  50. Varis A, Puolakkainen P, Savolainen H, et al.  DNA copy number profiling in esophageal Barrett adenocarcinoma (Comparison with gastric adenocarcinoma and esophageal squamous cell carcinoma). Cancer Genet Cytogenet. 2001;127:53–58
  51. Ebert MP, Malfertheiner P. Review article (Pathogenesis of sporadic and familial gastric cancer—Implications for clinical management and cancer prevention). Aliment Pharmacol Ther. 2002;16:1059–1066
  52. Guilford PJ, Hopkins JB, Grady WM, et al.  E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer. Hum Mutat. 1999;14:249–255
  53. Nardone G. Review article (Molecular basis of gastric carcinogenesis). Aliment Pharmacol Ther. 2003;17(suppl 2):75–81
  54. Ougolkov A, Yamashita K, Bilim V, et al.  Abnormal expression of E-cadherin, beta-catenin, and c-erbB-2 in advanced gastric cancer (Its association with liver metastasis). Int J Colorectal Dis. 2003;18:160–166
  55. Hara T, Ooi A, Kobayashi M, et al.  Amplification of c-myc, K-sam, and c-met in gastric cancers (Detection by fluorescence in situ hybridization). Lab Invest. 1998;78:1143–1153
  56. Vissers KJ, Riegman PH, Alers JC, et al.  Involvement of cancer-activating genes on chromosomes 7 and 8 in esophageal (Barrett’s) and gastric cardia adenocarcinoma. Anticancer Res. 2001;21:3813–3820
  57. Hu YC, Lam KY, Law S, et al.  Profiling of differentially expressed cancer-related genes in esophageal squamous cell carcinoma (ESCC) using human cancer cDNA arrays (Overexpression of oncogene MET correlates with tumor differentiation in ESCC). Clin Cancer Res. 2001;7:3519–3525
  58. Yu J, Ebert MP, Miehlke S, et al.  alpha-catenin expression is decreased in human gastric cancers and in the gastric mucosa of first degree relatives. Gut. 2000;46:639–644
  59. El-Rifai W, Frierson HF, Moskaluk CA, et al.  Genetic differences between adenocarcinomas arising in Barrett’s esophagus and gastric mucosa. Gastroenterology. 2001;121:592–598
  60. Heim S, Mitelman F. Cancer Cytogenetics. (ed 2). New York, NY: Wiley-Liss; 1995;
  61. van Dekken H, Geelen E, Dinjens WN, et al.  Comparative genomic hybridization of cancer of the gastroesophageal junction (deletion of 14Q31-32.1 discriminates between esophageal (Barrett’s) and gastric cardia adenocarcinomas). Cancer Res. 1999;59:748–752
  62. Taniere P, Borghi-Scoazec G, Saurin JC, et al.  Cytokeratin expression in adenocarcinomas of the esophagogastric junction (A comparative study of adenocarcinomas of the distal esophagus and of the proximal stomach). Am J Surg Pathol. 2002;26:1213–1221
  63. Taniere P, Martel-Planche G, Maurici D, et al.  Molecular and clinical differences between adenocarcinomas of the esophagus and of the gastric cardia. Am J Pathol. 2001;158:33–40
  64. Yanagi M, Keller G, Mueller J, et al.  Comparison of loss of heterozygosity and microsatellite instability in adenocarcinomas of the distal esophagus and proximal stomach. Virchows Arch. 2000;437:605–610
  65. van Dekken H, Alers JC, Riegman PH, et al.  Molecular cytogenetic evaluation of gastric cardia adenocarcinoma and precursor lesions. Am J Pathol. 2001;158:1961–1967
  66. Imoto I, Yang ZQ, Pimkhaokham A, et al.  Identification of cIAP1 as a candidate target gene within an amplicon at 11q22 in esophageal squamous cell carcinomas. Cancer Res. 2001;61:6629–6634
  67. Noguchi T, Kimura Y, Takeno S, et al.  Chromosomal imbalance in esophageal squamous cell carcinoma (3q gain correlates with tumor progression but not prognostic significance). Oncol Rep. 2003;10:1393–1400
  68. Yen CC, Chen YJ, Chen JT, et al.  Comparative genomic hybridization of esophageal squamous cell carcinoma (Correlations between chromosomal aberrations and disease progression/prognosis). Cancer. 2001;92:2769–2777
  69. Wang Q, Wang B, Guan X, et al.  Analysis of comparative genomic hybridization and loss of heterozygosity in 43 primary gastric carcinomas. Chin Med J (Engl). 2003;116:517–523
  70. Sakakura C, Mori T, Sakabe T, et al.  Gains, losses, and amplifications of genomic materials in primary gastric cancers analyzed by comparative genomic hybridization. Genes Chromosomes Cancer. 1999;24:299–305
  71. Pimkhaokham A, Shimada Y, Fukuda Y, et al.  Nonrandom chromosomal imbalances in esophageal squamous cell carcinoma cell lines (Possible involvement of the ATF3 and CENPF genes in the 1q32 amplicon). Jpn J Cancer Res. 2000;91:1126–1133
  72. Dolan K, Garde J, Gosney J, et al.  Allelotype analysis of oesophageal adenocarcinoma (Loss of heterozygosity occurs at multiple sites). Br J Cancer. 1998;78:950–957

☆ Supported by National Institutes of Health T32 Surgical Oncology Research Training Program CA009672-13 and National Cancer Institute Grant No. CA71606

PII: S0093-7754(04)00240-4

doi: 10.1053/j.seminoncol.2004.04.019

Seminars in Oncology
Volume 31, Issue 4 , Pages 476-486 , August 2004

Article Tools

* Image Usage & Resolution